News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Is It Time to Break Up Amgen (AMGN)?



6/6/2014 8:03:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Yes, says Bernstein’s Geoffrey Porges and Wen Shi, who look at the possibilities for “intrepid or activist investors” to create value in Amgen (AMGN).

There’s no question that Amgen’s stock has been a disappointment. Last year, its shares gained 35%, barely trumping the S&P 500's 32% return, while big competitors like Biogen Idec (BIIB) and Gilead Sciences (GILD) gained more than twice that.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES